Exploiting butyrylcholinesterase inhibitors through a combined 3-D pharmacophore modeling, QSAR, molecular docking, and molecular dynamics investigation. Issue 14 (23rd March 2023)

• Record Type: Journal Article
• Authors: Kumar, Sunil; Manoharan, Amritha; J, Jayalakshmi; Abdelgawad, Mohamed A.; Mahdi, Wael A.; Alshehri, Sultan; Ghoneim, Mohammed M.; Pappachen, Leena K.; Zachariah, Subin Mary; Aneesh, T. P.; Mathew, Bijo
• Is Part Of: RSC advances. Volume 13:Issue 14(2023)
• Page Start: 9513
• Page End: 9529
• Publication Date: 2023-03-23
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d3ra00526g
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Alzheimer's disease (AD), a neurodegenerative condition associated with ageing, can occur. Abstract : Alzheimer's disease (AD), a neurodegenerative condition associated with ageing, can occur. AD gradually impairs memory and cognitive function, which leads to abnormal behavior, incapacity, and reliance. By 2050, there will likely be 100 million cases of AD in the world's population. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibition are significant components of AD treatment. This work developed models using the genetic method multiple linear regression, atom-based, field-based, and 3-D pharmacophore modelling. Due to internal and external validation, all of the models have solid statistical ( R 2 > 0.81 and Q 2 > 0.77) underpinnings. From a pre-plated CNS library (6055), we discovered a hit compound using virtual screening on a QSAR model. Through molecular docking, additional hit compounds were investigated (XP mode). Finally, a molecular dynamics simulation revealed that the Molecule5093 -; 4BDS complex was stable (100 ns). Finally, the expected ADME properties for the hit compounds (Molecule5093, Molecule1076, Molecule4412, Molecule1053, and Molecule3344 ) were found. According to the results of our investigation and the prospective hit compounds, BuChE inhibitors may be used as a treatment for AD.